Merck to Present Rebif® (interferon beta-1a) and Investigational Cladribine Tablets Data at AAN 2017  

Merck to Present Rebif® (interferon beta-1a) and Investigational Cladribine Tablets Data at AAN 2017

Rebif (interferon beta-1a) Presentations
Abstract/ Presentation
Title Lead Author Poster # Date/Time/Session

Cholecalciferol W. Camu 004 April 27, 2017, 4:06 p.m.
Supplementation in Oral Presentation
Relapsing Multiple Session S44: MS Risk
Sclerosis Patients Treated Factors and Modifications
with Subcutaneous
Interferon Beta-1a: A
Randomized Controlled

High Dose Cholecalciferol R. Hupperts 005 April 27, 2017, 4:18 p.m.
(Vitamin D3) Oil as Add-on Oral Presentation
Therapy in Subjects with Session S44: MS Risk
Multiple Sclerosis
Receiving Subcutaneous
Interferon ss-1a

Treatment with Interferon M. Battaglini 340 April 28, 2017, 4:00 –
Reduces the Appearance of 5:30 p.m.
Lesions in Clinically Poster Session P6
Relevant White Matter (WM)
Tracts in Patients with
Clinically Isolated
Syndrome (CIS)

Effect of Early Versus M. Freedman 358 April 28, 2017, 4:00 –
Delayed Treatment (DT) 5:30 p.m.
with Subcutaneous IFN Poster Session P6
ss-1a (scIFNss-1a) on
Radiological Activity Free
(RAF) or Clinical Activity
Free (CAF) Status in
Patients with Clinically
Isolated Syndrome (CIS): A
Post-hoc Analysis of

Clinical Efficacy of F. Nelson 343 April 28, 2017, 4:00 –
Interferon ss-1a 5:30 p.m.
Subcutaneously Three Times Poster Session P6
Weekly According to
Baseline Radiological
Characteristics: Post Hoc
Analyses of PRISMS Data

Efficacy of Interferon E. Williamson 329 April 28, 2017, 4:00 –
ss-1a Subcutaneously Three 5:30 p.m.
Times Weekly According to Poster Session P6
Baseline EDSS/Duration,
EDSS, and MSSS Sub-groups:
Post Hoc Analysis of


Cladribine Tablets Presentations
Abstract/ Presentation
Title Lead Author Poster # Date/Time/Session

Cladribine Tablets in the S. Cook 394 April 27, 2017, 5:30 –
Treatment of Patients with 7:00 p.m.
Multiple Sclerosis (MS): Poster Session P5
An Integrated Analysis of
Safety from the MS
Clinical Development

Absolute Lymphocyte Count P. 379 April 27, 2017, 5:30 –
Recovery in Patients with Soelberg- 7:00 p.m.
Relapsing-Remitting Sorensen Poster Session P5
Multiple Sclerosis (RRMS)
Treated with Cladribine
Tablets 3.5 mg/kg in

Cladribine Tablets in the G. Comi 349 April 28, 2017, 4:00 –
ORACLE-MS Study Open-label 5:30 p.m.
Maintenance Period: Poster Session P6
Analysis of Efficacy in
Patients after Conversion
to Clinically Definite
Multiple Sclerosis (CDMS)

Defining High Disease G. Giovannoni 351 April 28, 2017, 4:00 –
Activity (HDA) in Patients 5:30 p.m.
with Relapsing Multiple Poster Session P6
Sclerosis (RMS) Receiving
Placebo in the CLARITY

Durable Efficacy of G. Giovannoni 353 April 28, 2017, 4:00 –
Cladribine Tablets in 5:30 p.m.
Patients with Multiple Poster Session P6
Sclerosis: Analysis of
Relapse Rates and
Relapse-free Patients in
Extension Studies

Efficacy of Cladribine G. Giovannoni 360 April 28, 2017, 4:00 –
Tablets 3.5 mg/kg in High 5:30 p.m.
Disease Activity (HDA) Poster Session P6
Subgroups of Patients with
Relapsing Multiple
Sclerosis (RMS) in the


Additional Company-Sponsored Presentations
Abstract/ Presentation
Title Lead Author Poster # Date/Time/Session

Multiple Sclerosis Relapse A. Phillips 361 April 23, 2017, 4:00 –
Rates, Before, During, and 5:30 p.m.
After Pregnancy: A US Poster Session P1
Retrospective Claims
Database Analysis

Pregnancy Complications of MK. Houtchens 110 April 24, 2017, 8:30
Women With and Without a.m. – 7:00 p.m.
Multiple Sclerosis in a Poster Session P2
Large US Claims Database

Does Patients’ Experience J. Smrtka 337 April 25, 2017, 5:30 –
of Care Differ by Level of 7:00 p.m.
Adherence in Multiple Poster Session P3


Leave a Reply

Your email address will not be published.

Time limit is exhausted. Please reload the CAPTCHA.